Monoclonal Origin of Anatomically Distinct Basal Cell Carcinomas: Is there Really Hard Evidence at Hand?  by van Steensel, Maurice A.M. & Frank, Jorge
ethnic origin and photosensitivity. FASEB J
17:1177–9
Tadokoro T, Yamaguchi Y, Batzer J, Coelho SG,
Zmudzka BZ, Miller SA et al. (2005)
Mechanisms of skin tanning in different
racial/ethnic groups in response to ultraviolet
radiation. J Invest Dermatol 124:1326–32
Tanner B, Grimme S, Schiffer I, Heimerdinger C,
Schmidt M, Dutkowski P et al. (2004)
Nuclear expression of apurinic/apyrimidinic
endonuclease increases with progression of
ovarian carcinomas. Gynecol Oncol
92:568–77
Tell G, Damante G, Caldwell D, Kelley MR (2005)
The intracellular localization of APE1/Ref-1:
more than a passive phenomenon? Antioxid
Redox Signal 7:367–84
Tell G, Pellizzari L, Pucillo C, Puglisi F, Cesselli D,
Kelley MR et al. (2000a) TSH controls Ref-1
nuclear translocation in thyroid cells. J Mol
Endocrinol 24:383–90
Tell G, Zecca A, Pellizzari L, Spessotto P,
Colombatti A, Kelley MR et al. (2000b) An
‘‘environment to nucleus’’ signaling system
operates in B lymphocytes: redox status
modulates BSAP/Pax-5 activation through
Ref-1 nuclear translocation. Nucleic Acids
Res 28:1099–105
Vile GF (1997) Active oxygen species mediate
the solar ultraviolet radiation-dependent
increase in the tumour suppressor protein
p53 in human skin fibroblasts. FEBS Lett
412:70–4
Virador V, Muller J, Wu X, Abdel-Malek ZA, Yu
Z-X, Ferrans VJ et al. (2002) Influence of
a-melanocyte stimulating hormone and
ultraviolet radiation on the transfer of mela-
nosomes to keratinocytes. FASEB J 16:105–7
Yamaguchi Y, Takahashi K, Zmudzka BZ, Korn-
hauser A, Miller SA, Tadokoro T et al. (2006)
Human skin responses to UV radiation:
pigment in the upper epidermis protects
against DNA damage in the lower
epidermis and facilitates apoptosis. FASEB J
(in press)
Yang S, Irani K, Heffron SE, Jurnak F, Meyskens FL
(2005) Alterations in the expression
of the apurinic/apyrimidinic endonuclease-
1/redox factor-1 (APE/Ref-1) in human mel-
anoma and identification of the thera-
peutic potential of resveratrol as an
APE/Ref-1 inhibitor. Mol Cancer Ther 4:
1923–35
Yao KS, Clayton M, O’Dwyer PJ (1995) Apoptosis
in human adenocarcinoma HT29 cells in-
duced by exposure to hypoxia. J Natl Cancer
Inst 87:117–22
Monoclonal Origin of Anatomically Distinct Basal Cell
Carcinomas: Is there Really Hard Evidence at Hand?
Journal of Investigative Dermatology (2006) 126, 2727–2729. doi:10.1038/sj.jid.5700471; published online 27 July 2006
TO THE EDITOR
It was with considerable surprise that
we read the recent publication by
Shulman et al. (2006) in the March
2006 issue of the JID. In that, the
authors employ X-inactivation and loss
of heterozygosity (LOH) studies at
9q22.3 to support their hypothesis that
basal cell carcinomas (BCCs) arising at
distinct anatomical sites in one affected
individual are of monoclonal origin
(Shulman et al., 2006). We think that
their interpretation and experimental
approach are largely invalid, mainly
for three reasons.
First, BCC grows slowly and rarely or
never metastasizes (Williams, 2003).
This latter fact and common sense make
it highly unlikely that this tumor would
discontinuously spread to anatomically
distinct body sites far beyond its point
of origin. If multifocal BCCs could
indeed arise as the result of separate
LOH events in a single tumor cell
clone, the entire anatomical region
encompassing the different sites would
be expected to carry a PTCH mutation
or other pre-existent genetic defect
(Reifenberger et al., 2005). For PTCH,
this would constitute a type 2 segmen-
tal manifestation of basal cell nevus
syndrome, analogous to what has been
recently described for other autosomal
dominantly inherited genodermatoses
as, for example, Hailey–Hailey disease
(Poblete-Gutierrez et al., 2004). The
authors do not deliver any such mole-
cular evidence to strengthen their argu-
ment. Patients should have been
screened for the presence of germline
PTCH mutations.
Second, the way in which the
authors designed their LOH studies
seems inadequate to us in proving their
theory. We do not dispute that the
chromosomal region on 9q22.3 harbor-
ing the PTCH gene plays a crucial role
in any LOH study addressing BCC, but
the PTCH gene is outside of the
genomic interval defined by
STSA002A37 and D9S287 (Figure 1).
Therefore, LOH at one or both markers
does not necessarily imply LOH of
the PTCH gene and may be entirely
irrelevant to tumor development.
The gene itself should have been
sequenced in tumor material. Finding
recurrent mutations in distinct BCCs
would have supported the authors’
hypothesis.
Additionally, the fact that the same
two polymorphic markers on 9q22.3
studied by Shulman et al. are lost in 20
out of 30 tumors does not prove that all
these BCCs are of monoclonal origin.
We believe that chance loss of the same
allele in 20 out of 30 tumors is quite
possible, particularly when considering
that this merely occurred in seven
patients out of 15, with one of those
patients accounting for no less than four
out of 20 tumors studied. The two
markers are at 2 Mb distance (Figure 1).
Thus, it is not possible to exclude that
chance recombination events have
contributed to Shulman et al.’s findings.
Additional markers should have been
typed to resolve this matter. Also, the
authors did not consider that the
genomic structure of the region in
which the markers reside could cause
preferential loss of one marker. LOH
predominantly occurs at D9S287.
When looking at the sequence, this
marker is close to a LINE repeat. It is
known that such genomic elements will
increase the frequency of recombina-
tion (Zhou et al., 2001), which may
explain the observation of preferential
LOH at D9S287. In addition, theAbbreviations: BCC, basal cell carcinoma; LOH, loss of heterozygosity
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authors did apparently not take into
consideration that other genes and
chromosomal loci have already been
demonstrated to be important players in
the molecular pathogenesis of BCCs
(Ling et al., 2001; Reifenberger et al.,
2005).
Third, we think that the pattern of
X-inactivation is neither a reliable nor a
convincing indicator of clonality,
although we are aware that X-inactiva-
tion based clonality assays for evalua-
tion of human epithelial tumors have
been utilized in the past and are well
documented (for a review see e.g.
Chuaqui et al., 1998). Extreme lyoniza-
tion forms a considerable limitation of
these assays, because it can mimic
clonal derivation of cells (Kristiansen
et al., 2005). Therefore, skewed lyoni-
zation in healthy females represents the
major disadvantage of X-chromosome-
based clonality assays as employed by
Shulman et al. (Busque et al., 1996; El
Kassar et al., 1998). Because most
techniques are based on the difference
in DNA methylation between active
and inactive X-chromosomes, incom-
plete DNA digestion may occur, giving
an unreliable clonality result (El Kassar
et al., 1998). The X-inactivation pattern
is established during early embryogen-
esis (Happle, 1985). Of note, the
authors performed their studies in pre-
dominantly elderly women, with just
two out of 20 patients being younger
Figure 1. Marker location relative to the PTCH gene. (http://genomce.ucsc.edu).
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than 60 (Shulman et al., 2006). With
aging, acquired skewing occurs in
normal females and is present in 38%
of women over the age of 60 years
(Busque et al., 1996), whereas truly
random lyonization is rare (El Kassar
et al., 1998). Whether acquired skew-
ing is a consequence of stem cell
depletion, true clonal tumor expansion,
growth advantage conferred by paren-
tal-specific X-chromosomes, or other
unknown mechanisms has not been
elucidated yet. Unfortunately, the
authors do not address the putative
influence of skewing on the outcome
of their study, although the broad range
of variation conferred by this mecha-
nism might provide a better explanation
for their data. A further disadvantage of
X-chromosome inactivation studies of
tumors is that they are only informative
when interpreted in the context of the
clonal composition of the surrounding
normal tissue and correlated with an
adequate sample number of normal
control tissue from age-matched indivi-
duals (Novelli et al., 2003). We feel that
the latter aspect was also insufficiently
addressed by Shulman et al. because
they did not incorporate age-matched
controls for lyonization. Another im-
portant factor, often ignored in such
studies, is the distribution of X-inacti-
vated cells in tissues. Taking into
consideration that lyonization occurs
early in development, many of the
progeny of a single embryonic stem
cell are grouped together in the adult,
forming patches. As polyclonality can
only be demonstrated at the borders of
X-inactivation patches, not only the
patch size is crucial in determining
the chance of demonstrating polyclon-
ality but also the number of tumors that
need to be examined to exclude poly-
clonality (Novelli et al., 2003) – one
more aspect not considered by the
authors.
In conclusion, we believe that the
authors did not deliver sufficient evi-
dence to support their theory that
anatomically and temporally distinct
BCCs can originate from one single
tumor cell clone.
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TO THE EDITOR
To the comments and concerns raised
by Drs van Steensel and Frank ( Journal
of Investigative Dermatology advance
online publication, 27 July 2006, doi:
10.1038/sj.jid.5700471), regarding the
main conclusion contained in our
manuscript ‘‘Monoclonal origin of ana-
tomically distinct basal cell carcino-
mas’’ (Shulman et al., 2006), we offer
the following responses:
1. It was never claimed anywhere by
us in the manuscript that the clone
precursor cell of anatomically dis-
tinct basal-cell carcinoma (BCC)
represents a metastatic process. If
we use the classical example of
another disorder, namely McCune–
Albright syndrome (OMIM# 174800),
it is clear that in this syndrome,
there is a post-zygotic mutation in
the Gs alpha gene – so-called gsp
mutation – that is contained in all
affected tissues (cafe´ au lait spots
included), and has been acquired
during embryogenesis (Weinstein
et al., 1991). It is evident that the
McCune–Albright syndrome is notAbbreviations: BCC, basal-cell carcinoma; LOH, loss of heterozygosity; PTCH, patched
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